Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?

Autor: Andre Fischer
Rok vydání: 2013
Předmět:
metabolism [Histones]
enzymology [Brain]
chemistry [Histone Demethylases]
chemistry [Histone Acetyltransferases]
Disease
Epigenesis
Genetic
Histones
drug effects [Methylation]
metabolism [Histone Demethylases]
therapeutic use [Histone Deacetylase Inhibitors]
agonists [Nerve Tissue Proteins]
Medicine
drug therapy [Alzheimer Disease]
Molecular Targeted Therapy
drug effects [Protein Processing
Post-Translational]
genetics [Nerve Tissue Proteins]
Nootropic Agents
Histone Acetyltransferases
Histone Demethylases
Neurons
enzymology [Neurons]
biology
therapeutic use [Nootropic Agents]
Brain
Acetylation
drug effects [Epigenesis
Genetic]
metabolism [Histone Acetyltransferases]
drug effects [Up-Regulation]
3. Good health
Up-Regulation
Histone
metabolism [Neurons]
pharmacology [Nootropic Agents]
genetics [Histone Acetyltransferases]
drug effects [Brain]
metabolism [Histone-Lysine N-Methyltransferase]
genetics [Histone-Lysine N-Methyltransferase]
metabolism [Alzheimer Disease]
Nerve Tissue Proteins
genetics [Histone Demethylases]
Methylation
Models
Biological
Cellular and Molecular Neuroscience
Alzheimer Disease
drug effects [Neurons]
Dementia
Animals
Humans
ddc:610
Epigenetics
Pharmacology
metabolism [Nerve Tissue Proteins]
business.industry
enzymology [Alzheimer Disease]
chemistry [Histone-Lysine N-Methyltransferase]
antagonists & inhibitors [Nerve Tissue Proteins]
Histone-Lysine N-Methyltransferase
medicine.disease
Histone Deacetylase Inhibitors
Gene Expression Regulation
metabolism [Brain]
biology.protein
drug effects [Acetylation]
business
Neuroscience
Protein Processing
Post-Translational
pharmacology [Histone Deacetylase Inhibitors]
Zdroj: Neuropharmacology 80, 95-102 (2014). doi:10.1016/j.neuropharm.2014.01.038
ISSN: 1873-7064
Popis: Alzheimer' s disease (AD) is the most common form of dementia causing an increasing emotional and economical burden to our societies. Although much progress has been made regarding the molecular mechanisms that underlie AD pathogenesis effective therapies are not available yet. The emerging field of neuroepigenetics has provided evidence that de-regulation of epigenetic processes play a role in AD. In this article we will critically review the primary research data that led to the hypothesis that targeting histone-modifying enzymes could be used to treat AD pathogenesis and address the question if the field is ready to translate such findings into clinical application.
Databáze: OpenAIRE
Externí odkaz: